Biogen Inc. Files 2025 DEF 14A on Executive Compensation
Ticker: BIIB · Form: DEF 14A · Filed: Apr 28, 2025 · CIK: 875045
| Field | Detail |
|---|---|
| Company | Biogen Inc. (BIIB) |
| Form Type | DEF 14A |
| Filed Date | Apr 28, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, corporate-governance, proxy-statement
Related Tickers: BIIB
TL;DR
Biogen's 2025 DEF 14A is out, detailing exec pay and historical financials. Focus on equity awards for folks like Vounatsos.
AI Summary
Biogen Inc. filed its DEF 14A on April 28, 2025, detailing executive compensation and corporate governance matters for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted to executive officers, such as Mr. Vounatsos, and adjustments to compensation. It also provides historical financial data for the years 2020 through 2023.
Why It Matters
This filing provides transparency into how Biogen Inc. compensates its top executives, which can influence investor decisions and perceptions of the company's management and financial health.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine but can reveal details about executive compensation and corporate governance that may impact investor sentiment and stock price.
Key Numbers
- 2020-2023 — Historical Financial Data (Periods covered by historical financial information in the filing)
Key Players & Entities
- Biogen Inc. (company) — Filer of the DEF 14A
- Mr. Vounatsos (person) — Executive officer mentioned in relation to compensation
- 20250428 (date) — Filing date of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for which compensation details are provided
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit proxies from shareholders for an upcoming annual or special meeting. It provides detailed information on matters to be voted on, including executive compensation, director elections, and other corporate governance issues.
Who is Mr. Vounatsos and what is his role in relation to the compensation data?
While the filing mentions 'biib:Mr.vounatsosMember' in the context of equity awards and compensation tables for the 2020 fiscal year, specific details about his current role or exact compensation are not fully elaborated in the provided snippet. He appears to be an executive or board member whose compensation is detailed.
What fiscal years are covered by the historical financial data mentioned in the filing?
The filing references historical financial data for the fiscal years 2020, 2021, 2022, and 2023.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 28, 2025.
What is the reported fiscal year end for Biogen Inc.?
Biogen Inc.'s fiscal year ends on December 31.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 28, 2025 by Mr. Vounatsos regarding BIOGEN INC. (BIIB).